Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904046 · ClinicalTrials.gov registry record · NA
Pathophysiology of Uric Acid Nephrolithiasis
A NA study of Uric Acid Kidney Stone Disease, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 172
- Enrollment target
- 1
- Study location
NCT00904046: Completed NA study of Uric Acid Kidney Stone Disease, sponsored by University of Texas Southwestern Medical Center.
NCT00904046 is a NA study of Uric Acid Kidney Stone Disease that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 172 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904046, a NA study of Uric Acid Kidney Stone Disease, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 172 participants
- Enrollment target
- 1
- Study location
Study Summary
This study has two aims: Aim 1: To determine the presence of accumulation of fat within cells and the functional consequences of this in the kidney by correlating kidney fat content with urine test results. Aim 2: The investigators will evaluate the effect of thiazolidinedione (pioglitazone) on excess fatty acid accumulation in kidney tissue and its correlation with uric acid stone formation in subjects with uric acid stones. Pioglitazone is already U.S. Food \& Drug Administration (FDA)-approved for the treatment of type 2 diabetes, but is not approved by the FDA for treating or preventing or diagnosing stone risk.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pioglitazone
Study Locations (1)
Texas
- UT Southwestern Medical Center - Center for Mineral Metabolism - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2010-01-15 |
| Est. Completion | 2017-11-16 |
| Phase | NA |
What the finished NCT00904046 record still lists
NCT00904046 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Uric Acid Kidney Stone Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00904046 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00904046 about?
NCT00904046 is a clinical study titled "Pathophysiology of Uric Acid Nephrolithiasis". This study has two aims: Aim 1: To determine the presence of accumulation of fat within cells and the functional consequences of this in the kidney by correlating kidney fat content with urine test results. Aim 2: The investigators will evaluate the effect of thiazolidinedione (pioglitazone) on ex...
What is the current status of trial NCT00904046?
This trial is currently completed. It is a NA study. The enrollment target is 172 participants. The study started on 2010-01-15. Estimated completion is 2017-11-16.
What conditions does trial NCT00904046 study?
This clinical trial studies the following conditions: Uric Acid Kidney Stone Disease.
What interventions are being tested in trial NCT00904046?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00904046?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00904046 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00904046's enrollment target sits among peer trials
172 612th of 2000 higher than 1,389 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI